RT Journal Article
T1 Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
A1 Bastos-Oreiro, Mariana
A1 Gutierrez, Antonio
A1 Reguera, Juan Luís
A1 Iacoboni, Gloria
A1 López-Corral, Lucía
A1 Terol, María José
A1 Ortíz-Maldonado, Valentín
A1 Sanz, Jaime
A1 Guerra-Dominguez, Luisa
A1 Bailen, Rebeca
A1 Mussetti, Alberto
A1 Abrisqueta, Pau
A1 Hernani, Rafael
A1 Luzardo, Hugo
A1 Sancho, Juan-Manuel
A1 Delgado-Serrano, Javier
A1 Salar, Antonio
A1 Grande, Carlos
A1 Bento, Leyre
A1 González de Villambrosía, Sonia
A1 García-Belmonte, Daniel
A1 Sureda, Anna
A1 Pérez-Martínez, Antonio
A1 Barba, Pere
A1 Kwon, Mi
A1 Martín García-Sancho, Alejandro
K1 CAR-T cell therapy
K1 real world evidence (RWE)
K1 refractory aggressive B cell lymphoma
K1 scholar-1 criteria
K1 standard of care (SOC)
AB Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 months, p
YR 2022
FD 2022-07-12
LK http://hdl.handle.net/10668/20580
UL http://hdl.handle.net/10668/20580
LA en
DS RISalud
RD Apr 7, 2025